166 related articles for article (PubMed ID: 29315502)
1. A Genome-Wide Association Study Identifies a Candidate Gene Associated With Atazanavir Exposure Measured in Hair.
Tamraz B; Huang Y; French AL; Kassaye S; Anastos K; Nowicki MJ; Gange S; Gustafson DR; Bacchetti P; Greenblatt RM; Hysi PG; Aouizerat BE
Clin Pharmacol Ther; 2018 Nov; 104(5):949-956. PubMed ID: 29315502
[TBL] [Abstract][Full Text] [Related]
2. A population pharmacokinetic model is beneficial in quantifying hair concentrations of ritonavir-boosted atazanavir: a study of HIV-infected Zimbabwean adolescents.
Ngara B; Zvada S; Chawana TD; Stray-Pedersen B; Nhachi CFB; Rusakaniko S
BMC Pharmacol Toxicol; 2020 Aug; 21(1):58. PubMed ID: 32746923
[TBL] [Abstract][Full Text] [Related]
3. Potential associations between atazanavir exposure and clinical outcome: a pharmacokinetic sub-study from the MODAt randomized trial.
Colella E; Cattaneo D; Galli L; Baldelli S; Clementi E; Galli M; Lazzarin A; Castagna A; Rusconi S; Spagnuolo V
New Microbiol; 2018 Apr; 41(2):106-111. PubMed ID: 29498742
[TBL] [Abstract][Full Text] [Related]
4. Potential association between rosuvastatin use and high atazanavir trough concentrations in ritonavir-treated HIV-infected patients.
Gervasoni C; Riva A; Rizzardini G; Clementi E; Galli M; Cattaneo D
Antivir Ther; 2015; 20(4):449-51. PubMed ID: 25279606
[TBL] [Abstract][Full Text] [Related]
5. Protease inhibitor levels in hair strongly predict virologic response to treatment.
Gandhi M; Ameli N; Bacchetti P; Gange SJ; Anastos K; Levine A; Hyman CL; Cohen M; Young M; Huang Y; Greenblatt RM;
AIDS; 2009 Feb; 23(4):471-8. PubMed ID: 19165084
[TBL] [Abstract][Full Text] [Related]
6. Association of Pharmacogenetic Markers With Atazanavir Exposure in HIV-Infected Women.
Tamraz B; Huang Y; French AL; Kassaye S; Anastos K; Nowicki MJ; Gange S; Gustafson DR; Bacchetti P; Greenblatt RM; Hysi PG; Aouizerat BE;
Clin Pharmacol Ther; 2020 Feb; 107(2):315-318. PubMed ID: 31562781
[No Abstract] [Full Text] [Related]
7. Is the unbound concentration of atazanavir of interest in therapeutic drug monitoring?
Metsu D; Seraissol P; Delobel P; Cinq-Frais C; Cuzin L; Izopet J; Chatelut E; Gandia P
Fundam Clin Pharmacol; 2017 Apr; 31(2):245-253. PubMed ID: 27664801
[TBL] [Abstract][Full Text] [Related]
8. Metabolic and kidney disorders correlate with high atazanavir concentrations in HIV-infected patients: is it time to revise atazanavir dosages?
Gervasoni C; Meraviglia P; Minisci D; Ferraris L; Riva A; Landonio S; Cozzi V; Charbe N; Molinari L; Rizzardini G; Clementi E; Galli M; Cattaneo D
PLoS One; 2015; 10(4):e0123670. PubMed ID: 25875091
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic.
Ray JE; Marriott D; Bloch MT; McLachlan AJ
Br J Clin Pharmacol; 2005 Sep; 60(3):291-9. PubMed ID: 16120068
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and Pharmacodynamics of Atazanavir in HIV-1-Infected Children Treated With Atazanavir Powder and Ritonavir: Combined Analysis of the PRINCE-1 and -2 Studies.
Sevinsky H; Zaru L; Wang R; Xu X; Pikora C; Correll TA; Eley T
Pediatr Infect Dis J; 2018 Jun; 37(6):e157-e165. PubMed ID: 29206748
[TBL] [Abstract][Full Text] [Related]
11. A randomized trial in healthy subjects to assess the bioequivalence of an atazanavir/cobicistat fixed-dose combination tablet versus administration as separate agents.
Sevinsky H; Tao X; Wang R; Ravindran P; Sims K; Xu X; Jariwala N; Bertz R
Antivir Ther; 2015; 20(5):493-500. PubMed ID: 25361436
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetics-based optimisation of atazanavir treatment: potential role of new genetic predictors.
Falvella FS; Ricci E; Cheli S; Resnati C; Cozzi V; Cattaneo D; Gervasoni C; Clementi E; Galli M; Riva A
Drug Metab Pers Ther; 2017 May; 32(2):115-117. PubMed ID: 28599374
[No Abstract] [Full Text] [Related]
13. Evaluation of atazanavir Ctrough, atazanavir genotypic inhibitory quotient, and baseline HIV genotype as predictors of a 24-week virological response in highly drug-experienced, HIV-infected patients treated with unboosted atazanavir.
Gianotti N; Seminari E; Guffanti M; Boeri E; Villani P; Regazzi M; Bigoloni A; Schira G; Tiberi S; Fusetti G; Lazzarin A; Castagna A
New Microbiol; 2005 Apr; 28(2):119-25. PubMed ID: 16035256
[TBL] [Abstract][Full Text] [Related]
14. Higher Atazanavir Plasma Exposure in Rats is Associated with Gut Microbiota Changes Induced by Cotrimoxazole.
Basilua JM; Sawoo O; Mangin I; Dossou-Yovo F; Boussard A; Chevillard L; Lutete GT; Eto B; Peytavin G; Pochart P
Curr Drug Metab; 2019; 20(11):898-906. PubMed ID: 31702484
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetic modelling of the changes in atazanavir plasma clearance caused by ritonavir plasma concentrations in HIV-1 infected patients.
Moltó J; Estévez JA; Miranda C; Cedeño S; Clotet B; Valle M
Br J Clin Pharmacol; 2016 Dec; 82(6):1528-1538. PubMed ID: 27447851
[TBL] [Abstract][Full Text] [Related]
16. Atazanavir concentration in hair is the strongest predictor of outcomes on antiretroviral therapy.
Gandhi M; Ameli N; Bacchetti P; Anastos K; Gange SJ; Minkoff H; Young M; Milam J; Cohen MH; Sharp GB; Huang Y; Greenblatt RM
Clin Infect Dis; 2011 May; 52(10):1267-75. PubMed ID: 21507924
[TBL] [Abstract][Full Text] [Related]
17. Risk of cardiovascular events among patients with HIV treated with atazanavir-containing regimens: a retrospective cohort study.
Rosenblatt L; Farr AM; Nkhoma ET; Nelson JK; Ritchings C; Johnston SS
BMC Infect Dis; 2016 Sep; 16():492. PubMed ID: 27643691
[TBL] [Abstract][Full Text] [Related]
18. Is the Risk of Myocardial Infarction in People With Human Immunodeficiency Virus (HIV) Associated With Atazanavir or Darunavir? A Nested Case-Control Study Within the French Hospital Database on HIV.
Costagliola D; Potard V; Lang S; de Castro N; Cotte L; Duval X; Duvivier C; Grabar S; Mary-Krause M; Partisani M; Ronot-Bregigeon S; Simon A; Tattevin P; Weiss L; Zucman D; Katlama C; Raffi F; Boccara F
J Infect Dis; 2020 Feb; 221(4):516-522. PubMed ID: 31828320
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of "unboosting" atazanavir in a randomized controlled trial among HIV-infected patients receiving tenofovir DF.
Harris M; Ganase B; Watson B; Hull MW; Guillemi SA; Zhang W; Saeedi R; Harrigan PR
HIV Clin Trials; 2017 Jan; 18(1):39-47. PubMed ID: 28067119
[TBL] [Abstract][Full Text] [Related]
20. Coupling of an Acyl Migration Prodrug Strategy with Bio-activation To Improve Oral Delivery of the HIV-1 Protease Inhibitor Atazanavir.
Subbaiah MAM; Meanwell NA; Kadow JF; Subramani L; Annadurai M; Ramar T; Desai SD; Sinha S; Subramanian M; Mandlekar S; Sridhar S; Padmanabhan S; Bhutani P; Arla R; Jenkins SM; Krystal MR; Wang C; Sarabu R
J Med Chem; 2018 May; 61(9):4176-4188. PubMed ID: 29693401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
